glp-1 agonist drugs oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies GLP-1 Oral Solution – Affordable

GLP-1R expression is lower in cells compared to and cells, resulting in relatively less direct action of GLP-1 on cells

Biomarkers including HbA1c, fasting insulin, lipid profiles, and body composition measurements provide the quantitative feedback needed to determine whether the combined approach is producing the intended metabolic effects, whether adjustments to formulation or dosing are needed, and whether the balance between the two therapies remains appropriate as a woman's physiology evolves through and beyond the menopausal transition

So I have another meal or a snack where that was not how my body operated prior to the GLP-1

Kapitza C, Nosek L, Jensen L, et al

According to the Canadian Adult Obesity Clinical Practice Guidelines, drug therapy for weight management is appropriate for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity

However, oral formulations have different bioavailability profiles and may require different dosing schedules